PL3829599T3 - Połączenie do stosowania w leczeniu pozaprzełykowych objawów refluksu żołądkowego - Google Patents

Połączenie do stosowania w leczeniu pozaprzełykowych objawów refluksu żołądkowego

Info

Publication number
PL3829599T3
PL3829599T3 PL19768909.4T PL19768909T PL3829599T3 PL 3829599 T3 PL3829599 T3 PL 3829599T3 PL 19768909 T PL19768909 T PL 19768909T PL 3829599 T3 PL3829599 T3 PL 3829599T3
Authority
PL
Poland
Prior art keywords
extra
treatment
combination
gastric reflux
oesophageal
Prior art date
Application number
PL19768909.4T
Other languages
English (en)
Inventor
Luigi Mercuri
Original Assignee
Drugs Minerals And Generics Italia S.R.L. In Forma Abbreviata D.M.G. Italia S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugs Minerals And Generics Italia S.R.L. In Forma Abbreviata D.M.G. Italia S.R.L. filed Critical Drugs Minerals And Generics Italia S.R.L. In Forma Abbreviata D.M.G. Italia S.R.L.
Publication of PL3829599T3 publication Critical patent/PL3829599T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734Alginic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/80Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10Carbonates; Bicarbonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
PL19768909.4T 2018-08-02 2019-08-02 Połączenie do stosowania w leczeniu pozaprzełykowych objawów refluksu żołądkowego PL3829599T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000007771A IT201800007771A1 (it) 2018-08-02 2018-08-02 Combinazione per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico
PCT/IB2019/056598 WO2020026205A1 (en) 2018-08-02 2019-08-02 Combination for use in the treatment of extra-oesophageal symptoms of gastric reflux

Publications (1)

Publication Number Publication Date
PL3829599T3 true PL3829599T3 (pl) 2025-05-12

Family

ID=63965891

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19768909.4T PL3829599T3 (pl) 2018-08-02 2019-08-02 Połączenie do stosowania w leczeniu pozaprzełykowych objawów refluksu żołądkowego

Country Status (8)

Country Link
EP (1) EP3829599B1 (pl)
ES (1) ES3010137T3 (pl)
HR (1) HRP20250219T1 (pl)
HU (1) HUE070898T2 (pl)
IT (1) IT201800007771A1 (pl)
PL (1) PL3829599T3 (pl)
RS (1) RS66522B1 (pl)
WO (1) WO2020026205A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120053480A (zh) * 2023-11-30 2025-05-30 远大医学营养科学(武汉)有限公司 一种西甲硅油及其乳剂和制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001795A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate-antacid combinations
ITRM20030154A1 (it) * 2003-04-03 2004-10-04 D M G Italia S R L Sciroppo antireflusso.
US8288362B2 (en) * 2004-05-07 2012-10-16 S.K. Pharmaceuticals, Inc. Stabilized glycosaminoglycan preparations and related methods
IT201600121601A1 (it) * 2016-11-30 2018-05-30 Nekkar Lab Srl Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo

Also Published As

Publication number Publication date
RS66522B1 (sr) 2025-03-31
ES3010137T3 (en) 2025-04-01
HRP20250219T1 (hr) 2025-04-11
HUE070898T2 (hu) 2025-07-28
IT201800007771A1 (it) 2020-02-02
EP3829599B1 (en) 2024-12-04
EP3829599C0 (en) 2024-12-04
EP3829599A1 (en) 2021-06-09
WO2020026205A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
IL276398A (en) Combined treatment for mastocytosis
LT3806898T (lt) Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui
SG11202008696RA (en) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
IL278155B (en) Preparations to relieve symptoms of menopause
PT4101454T (pt) Composições para utilização no tratamento da hipertensão
LT3687567T (lt) Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką
PL3522904T3 (pl) Ciekła kompozycja do stosowania w leczeniu refluksu żołądkowo- przełykowego
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL283031A (en) And will grow to treat the symptoms of overactivity in the gland
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL284032A (en) 3 beta-(benzyloxy)-17 alpha-methyl-paragan-5-en-20-one for use in the treatment of cognitive disorders
IL276697A (en) 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders
PL3829599T3 (pl) Połączenie do stosowania w leczeniu pozaprzełykowych objawów refluksu żołądkowego
PT3548006T (pt) Composição para utilização no tratamento de alterações intestinais
GB201603510D0 (en) Compositions for use in the treatment of neurological disease
IL284074A (en) Decorin for use in the treatment of diabetes
IT201700057635A1 (it) Composizione per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico
GB201820451D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820452D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820455D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
AU2016901605A0 (en) Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith